Comparison of Inhalational Versus Intravenous Tranexamic Acid in the Management of Hemoptysis
DOI:
https://doi.org/10.51253/pafmj.v76i1.10511Keywords:
Hemoptysis, Inhalational, Intravenous, Tranexamic acidAbstract
Objective: To assess the effectiveness of inhalational versus intravenous route administration of Tranexamic Acid for treatment of hemoptysis.
Study Design: Quasi-experimental study
Place and Duration of Study: Main Intensive Care Unit, Combined Military Hospital, Rawalpindi, Pakistan, from Aug 2022 to May 2023.
Methodology: Patients of either gender presenting to ICU with active hemoptysis with age >18 years and stable hemodynamically were included in the trial. Using a non-probability consecutive sampling technique, these participants were divided equally into two groups: Group-N (n=51), in which nebulized Tranexamic Acid was used, and Group-I (n=51), in which intravenous Tranexamic Acid was administered. Comorbidities, demographic characteristics, bleeding at 30 mins, 06 hours, and 12 hours, and adverse reactions to treatment were the parameters recorded among the groups.
Results: Gender distribution of 102 participants revealed male participants as 68(66.7%) versus 34(33.3%). The mean age of the patients in Group-N and Group-I was 48.82±8.96 years and 49.61±7.77 years, respectively. Amount of bleed after administration of Tranexamic Acid in Group-N was significantly lesser with a median amount of 0.7ml (IQR 0.5-2.0) as compared to Group-I with a median amount of 3ml (IQR 0.7-3.0) (p- value -0.047). Assessment of bleeding at 6 hours and 12 hours also revealed a significant reduction in Group-N compared to Group-I, with a p-value of <0.01.
Conclusion: Tranexamic Acid administered via inhalational route is more effective than the intravenous route for the treatment of hemoptysis.
Downloads
References
1. Kathuria H, Hollingsworth HM, Vilvendhan R, Reardon C. Management of life-threatening hemoptysis. J intensive care 2020; 8(1): 1-9.
https://doi.org/10.1186/s40560-020-00441-8
2. Davidson K, Shojaee S. Managing Massive Hemoptysis. Chest 2020; 157(1): 77-88.
https://doi:10.1016/j.chest.2019.07.012.
3. Ittrich H, Bockhorn M, Klose H, Simon M. The diagnosis and treatment of hemoptysis. Dtsch Arztebl Int 2017; 114(21): 371-381.https://doi.org/10.3238/arztebl.2017.0371
4. O'Gurek D, Choi HYJ. Hemoptysis: Evaluation and Management. Am Fam Physician 2022; 105(2): 144-151.
5. Lier H, Maegele M, Shander A. Tranexamic Acid for acute hemorrhage: a narrative review of landmark studies and a critical reappraisal of its use over the last decade. Anesthesia & Analgesia. 2019; 129(6): 1574-1584.
https://doi.org/10.1213/ane.0000000000004389
6. Goobie SM, Faraoni D. Tranexamic Acid and perioperative bleeding in children: what do we still need to know?. Curr Opin Anaesthesiol 2019 Jun 1; 32(3): 343-352.
https://doi.org/10.1097/aco.0000000000000728
7. Chauncey JM, Patel P. Tranexamic acid [Internet]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025 Jan [updated 2025 Apr 26; cited 2026 Jan 21]. Available from:
https://www.ncbi.nlm.nih.gov/books/NBK532909/
8. Prudovsky I, Kacer D, Zucco VV, Palmeri M, Falank C, Kramer R, et al.Tranexamic acid: Beyond antifibrinolysis. Transfusion 2022; 62 Suppl 1: S301-S312. https://doi:10.1111/trf.16976.
9. Lei YT, Xie JW, Huang Q, Huang W, Pei FX. The antifibrinolytic and anti-inflammatory effects of a high initial-dose tranexamic acid in total knee arthroplasty: a randomized controlled trial. Int Orthop 2020; 44(3): 477-486.
https://doi:10.1007/s00264-019-04469-w.
10. Franchini M, Mannucci PM. The never-ending success story of Tranexamic Acid in acquired bleeding. Haematologica 2020; 105(5): 1201-1205.
https://doi.org/10.3324/haematol.2020.250720
11. Gopinath B, Mishra PR, Aggarwal P, Nayaka R, Naik SR, Kappagantu V et al. Nebulized vs IV Tranexamic Acid for Hemoptysis: A Pilot Randomized Controlled Trial. Chest 2023 May; 163(5): 1176-1184.
https://doi.org/10.1016/j.chest.2022.11.021
12. Bafaqih H, Chehab M, Almohaimeed S, Thabet F, Alhejaily A, AlShahrani M et al. Pilot trial of a novel two-step therapy protocol using nebulized Tranexamic Acid and recombinant factor VIIa in children with intractable diffuse alveolar hemorrhage. Ann Saudi Med 2015; 35(3): 231-239.
https://doi.org/10.5144/0256-4947.2015.231
13. Slattery C, Kark J, Wagner T, Verma K. The use of Tranexamic Acid to reduce surgical blood loss. Clin Spine Surg 2019; 32(2): 46-50.
https://doi.org/10.1097/bsd.0000000000000808
14. Tille E, Mysliwietz J, Beyer F, Postler A, Lützner J. Intraarticular use of Tranexamic Acid reduces blood loss and transfusion rate after primary total knee arthroplasty. BMC Musculoskelet Disord 2019; 20(1): 1-6.
https://doi.org/10.1186/s12891-019-2715-9
15. Zhang YM, Yang B, Sun XD, Zhang Z. Combined intravenous and intra-articular Tranexamic Acid administration in total knee arthroplasty for preventing blood loss and hyperfibrinolysis: A randomized controlled trial. Medicine 2019; 98(7): e14458. https://doi.org/10.1097/md.0000000000014458
16. Xie J, Hu Q, Huang Z, Zhou Z, Pei F. Comparison of three routes of administration of Tranexamic Acid in primary unilateral total knee arthroplasty: Analysis of a national database. Thromb res 2019; 173: 96-101.
https://doi.org/10.1016/j.thromres.2018.11.025
17. Palija S, Bijeljac S, Manojlovic S, Jovicic Z, Jovanovic M, Cvijic P, Dragicevic-Cvjetkovic D. Effectiveness of different doses and routes of administration of Tranexamic Acid for total hip replacement. Int Orthop 2021; 45: 865-870.
https://doi.org/10.1007/s00264-020-04585-y
18. Wong J, George RB, Hanley CM, Saliba C, Yee DA, Jerath A. Tranexamic acid: current use in obstetrics, major orthopedic, and trauma surgery. Can J Anesth 2021; 68(6): 894-917.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Junaid Zafar, Khan Muhammad Yaqub, Sundas Shaukat, Kamil Hussain Qureshi, Muhammad Zulqarnain Saleem, Asif Jaleel
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
